• +1-646-491-9876
    • +91-20-67278686

    Search

    Herpes Zoster (Shingles) - Pipeline Review, H1 2017

    Herpes Zoster (Shingles) - Pipeline Review, H1 2017

    • Report Code ID: RW0001767474
    • Category Pharmaceuticals
    • No. of Pages 63
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Herpes Zoster (Shingles) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

    Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 3, 1, 1, 6 and 1 respectively.

    Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Herpes Zoster (Shingles) - Overview
    Herpes Zoster (Shingles) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Herpes Zoster (Shingles) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
    Astellas Pharma Inc
    Beijing Minhai Biotechnology Co Ltd
    ContraVir Pharmaceuticals Inc
    Epiphany Biosciences Inc
    Foamix Pharmaceuticals Ltd
    GeneOne Life Science Inc
    GlaxoSmithKline Plc
    Merck & Co Inc
    NAL Pharmaceuticals Ltd
    NanoViricides Inc
    SK Chemicals Co Ltd
    TSRL Inc
    XBiotech Inc
    Herpes Zoster (Shingles) - Drug Profiles
    acyclovir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amenamevir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FV-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GLS-5100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-1437173A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    herpes zoster vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Shingles - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NAL-3223 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NBP-608 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NN-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Shingles - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TSR-087 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    V-212 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    valomaciclovir stearate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Herpes Zoster (Shingles) - Dormant Projects
    Herpes Zoster (Shingles) - Discontinued Products
    Herpes Zoster (Shingles) - Product Development Milestones
    Featured News & Press Releases
    Apr 18, 2017: GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles
    Feb 24, 2017: In First Phase 3 Trial, Merck's Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
    Nov 25, 2016: GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
    Oct 27, 2016: GSK presents new data for shingles candidate vaccine at IDWeek scientific conference
    Oct 24, 2016: GSK announces US regulatory submission of candidate vaccine for prevention of shingles
    Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
    Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
    Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug
    Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
    Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
    Sep 08, 2015: Clinical trial for Cardiff's shingles treatment
    Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
    Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
    Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied
    Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Herpes Zoster (Shingles) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc, H1 2017
    Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
    Herpes Zoster (Shingles) - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
    Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences Inc, H1 2017
    Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
    Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H1 2017
    Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H1 2017
    Herpes Zoster (Shingles) - Pipeline by Merck & Co Inc, H1 2017
    Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
    Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H1 2017
    Herpes Zoster (Shingles) - Pipeline by SK Chemicals Co Ltd, H1 2017
    Herpes Zoster (Shingles) - Pipeline by TSRL Inc, H1 2017
    Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H1 2017
    Herpes Zoster (Shingles) - Dormant Projects, H1 2017
    Herpes Zoster (Shingles) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Herpes Zoster (Shingles) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Astellas Pharma Inc
    Beijing Minhai Biotechnology Co Ltd
    ContraVir Pharmaceuticals Inc
    Epiphany Biosciences Inc
    Foamix Pharmaceuticals Ltd
    GeneOne Life Science Inc
    GlaxoSmithKline Plc
    Merck & Co Inc
    NAL Pharmaceuticals Ltd
    NanoViricides Inc
    SK Chemicals Co Ltd
    TSRL Inc
    XBiotech Inc

    Request for Sample

    Report Url http://www.reportsweb.com//herpes-zoster-shingles-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//herpes-zoster-shingles-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//herpes-zoster-shingles-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments